Kristina Lovgren
Overview
Explore the profile of Kristina Lovgren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
2958
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Alkner S, Bendahl P, Ehinger A, Lovgren K, Ryden L, Ferno M
PLoS One
. 2016 Mar;
11(3):e0150977.
PMID: 26959415
Aim: The estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance....
12.
Kimbung S, Kovacs A, Danielsson A, Bendahl P, Lovgren K, Frostvik Stolt M, et al.
Oncotarget
. 2015 Sep;
6(32):33306-18.
PMID: 26375671
The relevance of the intrinsic subtypes for clinical management of metastatic breast cancer is not comprehensively established. We aimed to evaluate the prevalence and prognostic significance of drifts in tumor...
13.
Patschan O, Sjodahl G, Chebil G, Lovgren K, Lauss M, Gudjonsson S, et al.
Eur Urol
. 2015 Mar;
68(5):824-32.
PMID: 25770486
Background: One third of patients with stage T1 urothelial carcinoma (UC) progress to muscle-invasive disease requiring radical surgery. Thus, reliable tools are needed for risk stratification of stage T1 UC....
14.
Sjodahl G, Lovgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, et al.
Urol Oncol
. 2014 May;
32(6):791-7.
PMID: 24794251
Objectives: Urothelial carcinoma (UC) aggressiveness is determined by tumor inherent molecular characteristics, such as molecular subtypes, as well as by host reactions directed toward the tumor. Cell types responsible for...
15.
Ekholm M, Beglerbegovic S, Grabau D, Lovgren K, Malmstrom P, Hartman L, et al.
Histopathology
. 2014 Feb;
65(2):252-60.
PMID: 24527721
Aims: To compare SP6 and MIB1 antibodies for assessment of Ki67 in primary breast cancer with regard to prognostic value and reproducibility. Methods And Results: A cohort of 237 premenopausal...
16.
Klintman M, Strand C, Ahlin C, Beglerbegovic S, Fjallskog M, Grabau D, et al.
PLoS One
. 2013 Dec;
8(12):e81902.
PMID: 24324728
Proliferation, either as the main common denominator in genetic profiles, or in the form of single factors such as Ki67, is recommended for clinical use especially in estrogen receptor-positive (ER)...
17.
Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, et al.
Am J Pathol
. 2013 Jul;
183(3):681-91.
PMID: 23827819
We recently defined molecular subtypes of urothelial carcinomas according to whole genome gene expression. Herein we describe molecular pathologic characterization of the subtypes using 20 genes and IHC of 237...
18.
Broselid S, Cheng B, Sjostrom M, Lovgren K, Klug-De Santiago H, Belting M, et al.
Clin Cancer Res
. 2013 Apr;
19(7):1681-92.
PMID: 23554355
Purpose: G protein-coupled estrogen receptor 1 (GPER1), previously named GPR30, is a membrane receptor reported to mediate nongenomic estrogen responses. We investigated if GPER1 expression correlates with any clinicopathologic variables...
19.
Falck A, Bendahl P, Ingvar C, Isola J, Jonsson P, Lindblom P, et al.
BMC Cancer
. 2012 Sep;
12:403.
PMID: 22963449
Background: Disseminated tumour cells (DTCs) in the bone marrow of patients with breast cancer have been identified as an independent predictor of poor prognosis in patients with non-metastatic disease. This...
20.
Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J, et al.
Mol Oncol
. 2012 Jul;
6(5):494-506.
PMID: 22766277
Polycomb repressive complex 2 (PRC2) and its core member enhancer of zeste homolog 2 (EZH2) mediate the epigenetic gene silencing mark: trimethylation of lysine 27 on histone 3 (H3K27me3). H3K27me3...